Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Sclerosing Cholangitis: early-phase trial registry
15 of 24 indexed Primary Sclerosing Cholangitis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 15 currently recruiting · #686 of 28,707 conditions by registered trial count
Primary Sclerosing Cholangitis: 24 US clinical trials tracked, 15 recruiting.
Primary Sclerosing Cholangitis is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 4 of these trials.
Enrollment posture brief
Registry condition primary-sclerosing-cholangitis
OPEN 15 | RECR 63% | LATE 1 | EARLY 13 | RANK #686 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adolescent (63% recruiting · 16 trials)
Primary Sclerosing Cholangitis lists 15 open slots (63% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Sclerosing Cholangitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Sclerosing Cholangitis is recruiting above its size-band peers.
15 of 24 indexed trials (62.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Primary Sclerosing Cholangitis research.
Mayo Clinic accounts for 4 of 24 trials (16.7%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Primary Sclerosing Cholangitis enrolment sits around 80 participants.
Median target enrolment is 80 among the 24 trials that report a genuine target (sentinel values excluded). 13 of those (54.2%) plan for fewer than 100 participants.
-
Primary Sclerosing Cholangitis splits between interventional and observational designs.
16 interventional and 8 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Biobank for Cholestatic Liver Diseases.
Mayo Clinic
NCT03445585
Primary Sclerosing Cholangitis in Children
Arbor Research Collaborative for Health
NCT04181138
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
Children's Hospital Medical Center, Cincinnati
NCT05750498
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Mayo Clinic
NCT04753996
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Sacramento Pediatric Gastroenterology
NCT02137668
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Children's Hospital Medical Center, Cincinnati
NCT03178630
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT04685200
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
Takeda
NCT07229911
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Children's Hospital Medical Center, Cincinnati
NCT03175471
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Mayo Clinic
NCT06905054
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
University of Minnesota
NCT06197308
Detoxification of the Liver In PSC (Dolphin)
Brigham and Women's Hospital
NCT05835505
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Aparna Goel
NCT05295680
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
Stanford University
NCT05912387
A Study of SIPLIZUMAB in AILD and LT Patients
Elizabeth C. Verna
NCT06455280
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Mirum Pharmaceuticals
NCT04663308
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Ipsen
NCT05627362
Quality of Life in Patients With Primary Sclerosing Cholangitis
Duke University
NCT02712736
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
NGM Biopharmaceuticals
NCT02704364
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Stanford University
NCT01802073
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
Brigham and Women's Hospital
NCT03561584
Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)
Mayo Clinic
NCT00951327
A Pilot Study Examining Diet in Primary Sclerosing Cholangitis
Brigham and Women's Hospital
NCT04678219
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis
University of Minnesota
NCT02464020
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Sclerosing Cholangitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Sclerosing Cholangitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Sclerosing Cholangitis page
24 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Primary Sclerosing Cholangitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Primary Sclerosing Cholangitis trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Sclerosing Cholangitis condition card totals 24 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.